Abstract 1680P
Background
Chronic pain is reported by > 50% of patients recovering from breast cancer (BC). Adverse life experiences (ALEs) are associated with decreased psychosocial functioning in BC survivors, but their effect on pain has not been thoroughly explored. Sense of coherence (SOC) is the disposition to feel that life is predictable and manageable. Sense of danger (SOD) reflects expectations of harm from a particular event.
Methods
We are conducting a prospective study to assess if ALEs increase chronic adverse effects in patients with localized BC and identify mediating mechanisms. Patients are recruited before starting (neo)adjuvant oncological treatment and assessed periodically by validated questionnaires, including ALEs, SOC, SOD from BC, FACT-COG, FACT-ES, and brief pain inventory. Blood samples for inflammatory biomarkers are stored. This sub-study tested if ALEs are associated with baseline pain, measured as a composite score of pain intensity and interference, and examined the mediating role of SOC and SOD.
Results
Of 126 participants, 97 provided data on ALEs. Median age was 49 (range 23-75). 53.6% were treated in the neoadjuvant setting. Chemotherapy was planned for 62.9%. More ALEs correlated with more pain (r =. 34, p <. 001). Educational level and planned chemotherapy correlated with less pain. Serial mediation analysis revealed that after controlling for these variables, ALEs were indirectly associated with more pain through lower SOC followed by higher SOD from BC, CIs = 0.001, 0.103. Together, the model explained 38% of the variance in patients’ pain, F (5, 82) = 9.92, p <. 001. Age, BMI, CRP levels, and neutrophils to lymphocytes ratio were not associated with pain scores or with other study variables. Having surgery (vs planned surgery) was not associated with pain scores.
Conclusions
Exposure to a higher number of ALEs was associated with higher baseline pain in early BC patients before oncological treatment, mediated by decreased SOC and higher SOD from BC. These results stress the importance of addressing past trauma, sense of coherence, and sense of danger from BC to improve physical adverse effects such as pain. Further study will explore the effect of ALE, SOC, and SOD on pain persistence after adjuvant therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11